CDK2 and esophageal cancer: Moreover, ASPA can notably decrease the rate of growth and the ability to move in esophageal cancer cells, thereby diminishing the tumor’s resistance to 5-fluorouracil by curbing the expression of cyclin-dependent kinase 2 (CDK2) and E2F1 (25).